ALFERON N INJECTION
Clinical safety rating: caution
Comprehensive clinical and safety monograph for ALFERON N INJECTION (ALFERON N INJECTION).
Alferon N (interferon alfa-n3) is a natural interferon product that binds to interferon receptors, activating JAK-STAT signaling and inducing antiviral, antiproliferative, and immunomodulatory proteins like 2',5'-oligoadenylate synthetase and protein kinase R.
| Metabolism | Interferon alfa-n3 is eliminated primarily via renal catabolism; specific hepatic CYP enzyme involvement is not well-defined. |
| Excretion | Renal (metabolized in kidneys, <1% unchanged in urine); biliary/fecal elimination is minimal. |
| Half-life | Terminal elimination half-life is approximately 2-3 hours after intravenous administration, with clinical effects persisting due to post-receptor signaling. |
| Protein binding | Approximately 60-80% bound to albumin and alpha-2-macroglobulin. |
| Volume of Distribution | 0.4-0.6 L/kg, indicating distribution into total body water with limited tissue penetration. |
| Bioavailability | Intramuscular: ~70%; Subcutaneous: ~60-80%; Intravenous: 100%. |
| Onset of Action | Intramuscular injection: 1-2 hours; Subcutaneous injection: 2-4 hours; Intravenous injection: within minutes. |
| Duration of Action | Duration of clinical effect is 12-24 hours, with antiviral or immunomodulatory effects persisting beyond serum clearance. |
3 million IU subcutaneously or intramuscularly three times weekly.
| Dosage form | VIAL |
| Renal impairment | GFR 15-50 mL/min: reduce dose by 25%; GFR <15 mL/min or hemodialysis: administer 50% of standard dose. |
| Liver impairment | Child-Pugh class A: no adjustment; Child-Pugh class B: reduce dose by 25%; Child-Pugh class C: contraindicated. |
| Pediatric use | Not established; safety and efficacy in pediatric patients have not been determined. |
| Geriatric use | No specific dose adjustment based solely on age; monitor renal function and adjust accordingly. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for ALFERON N INJECTION (ALFERON N INJECTION).
| Breastfeeding | It is unknown whether interferon alfa-n3 is excreted in human breast milk. No M/P ratio data are available. Due to the potential for serious adverse reactions in nursing infants, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother. |
| Teratogenic Risk | Interferon alfa-n3 (ALFERON N INJECTION) is a pregnancy category C drug. Animal studies have shown embryocidal and abortifacient effects at high doses. There are no adequate and well-controlled studies in pregnant women. First trimester exposure may increase the risk of spontaneous abortion. Second and third trimester risks include potential fetal growth restriction and oligohydramnios due to maternal flu-like symptoms and hemodynamic changes. Risk cannot be excluded. |
■ FDA Black Box Warning
May cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Monitor closely and discontinue if severe reactions occur.
| Serious Effects |
["Hypersensitivity to interferon alfa or any component","Severe psychiatric history (e.g., depression, suicidality)","Decompensated liver disease","Autoimmune hepatitis"]
| Precautions | ["Neuropsychiatric effects including depression and suicidality","Autoimmune disorders","Myelosuppression","Cardiovascular events including ischemia","Pulmonary dysfunction","Ophthalmic disorders","Hepatotoxicity"] |
| Food/Dietary | No specific food interactions are documented. Avoid alcohol during treatment as it may worsen flu-like symptoms or hepatic side effects. |
Loading safety data…
| Fetal Monitoring | Monitor maternal complete blood count (CBC) with differential, liver function tests (LFTs), serum creatinine, and thyroid function tests (TSH, T4) at baseline and periodically thereafter. Monitor fetal growth and amniotic fluid volume by ultrasound every 4 weeks if used during second or third trimester. Assess for maternal hypotension, tachycardia, and flu-like symptoms. In pregnant patients, monitor for signs of preeclampsia. |
| Fertility Effects | Interferon alfa-n3 may impair fertility in females and males. In females, it can disrupt menstrual cycles and cause amenorrhea. In males, reversible oligospermia or azoospermia has been reported. Effects are generally reversible upon discontinuation. |
| Clinical Pearls | Alferon N (interferon alfa-n3) is a natural-source interferon used primarily for refractory or recurrent genital warts. Administer intralesionally only; do not use intravenously, subcutaneously, or intramuscularly. Premedicate with acetaminophen to reduce flu-like symptoms. Monitor CBC and LFTs at baseline and periodically. Efficacy is enhanced by treating all visible warts. Avoid use in patients with severe cardiac disease or autoimmune disorders. |
| Patient Advice | This medication is injected directly into the wart(s) by a healthcare provider; do not attempt to inject yourself. · You may experience flu-like symptoms (fever, chills, muscle aches) for several hours after injection; acetaminophen can help. · Multiple treatment sessions are usually required; complete the full course as prescribed. · Keep the injection site clean and dry; report any signs of infection or severe swelling. · Avoid sexual contact until warts are completely healed; use barrier protection to reduce transmission. |